Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235024 · ClinicalTrials.gov registry record · Phase 2
Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis
A Phase 2 study, sponsored by AOBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT03235024: Completed Phase 2 study, sponsored by AOBiome.
NCT03235024 is a Phase 2 study that has completed, run by AOBiome. The registered enrollment target is 122 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03235024, a Phase 2 study, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
Primary Outcome
Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL B244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2019-03-20 |
| Phase | Phase 2 |
What the finished NCT03235024 record still lists
NCT03235024 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03235024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03235024 about?
NCT03235024 is a clinical study titled "Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis". This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
What is the current status of trial NCT03235024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2018-01-15. Estimated completion is 2019-03-20.
What interventions are being tested in trial NCT03235024?
The interventions under investigation include: Vehicle (BIOLOGICAL), B244 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03235024?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03235024's enrollment target sits among peer trials
122 565th of 2000 higher than 1,434 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI